Maltosyl-isomaltooligosaccharides
The application describes compositions that include maltosyl-isomalto-oligosaccharides with a desirable mass average molecular weight distribution. In some cases, the compositions can contain at least 3% mannitol.
1. A method comprising administering to an animal a composition comprising maltosyl-isomaltooligosaccharides with a mass average molecular weight distribution of about 730 to 900 daltons, and where at least 60% of the maltosyl-isomaltooligosaccharides have at least 75% α-(1,6) linkages, and wherein at least 40% of the maltosyl-isomaltooligosaccharides in the composition have a degree of polymerization (DP) of 5 or more, wherein the animal has a disease or condition selected from a pre-cancerous condition, cancerous predispostion, acid reflux, bacterial infection, degraded intestinal mucosal lining, ulcerative colitis, Irritable Bowel Syndrome, constipation, gastroesophageal reflux disease (GERD), infectious enteritis, colon polyps, familial polyposis syndrome, Gardner's Syndrome, Helicobacter pylori infection, intestinal cancer, autoimmune disease, or a combination thereof.
2. The method of claim 1 , where the maltosyl-isomaltooligosaccharides have no more than about 18 glucose units.
3. The method of claim 1 , where the maltosyl-isomaltooligosaccharides have a maltose unit at the reducing end.
4. The method of claim 1 , wherein the composition has less than 2%/brix isomaltose.
5. The method of claim 1 , wherein the composition has less than 5%/brix glucose.
6. The method of claim 1 , wherein the composition has less than 5%/brix sucrose.
7. The method of claim 1 , wherein the composition has less than 4%/brix fructose.
8. The method of claim 1 , wherein the composition has less than 7%/brix lactate.
9. The method of claim 1 , wherein the composition has less than 8%/brix maltose.
10. The method of claim 1 , wherein the composition has 3% or more than 3%/brix mannitol.
11. The method of claim 1 , wherein the composition has less than 4%/brix glycerol.
12. The method of claim 1 , wherein the composition has less than 20%/brix MIMO-DP3.
13. The method of claim 1 , wherein the composition has less than 30%/brix MIMO-DP4.
14. The method of claim 1 , wherein the composition has more than 18%/brix MIMO-DP5.
15. The method of claim 1 , wherein the composition has more than 10%/brix MIMO-DP6.
16. The method of claim 1 , wherein the composition has more than 1%/brix MIMO-7.
17. The method of claim 1 , wherein the composition has more than 0.5%/brix MIMO-DP8.
18. The method of claim 1 , wherein the composition has more than 0.1%/brix MIMO-DP9.
19. The method of claim 1 , wherein the composition is a concentrated solution.
20. The method of claim 1 , wherein the composition is a powder.
21. The method of claim 1 , wherein the composition is aliquoted into individual servings for human or animal consumption.
22. The method of claim 1 , wherein the composition is aliquoted into individual serving of about 0.25 ml to about 10 ml.
23. The method of claim 1 , wherein the animal is a human, domesticated animal, zoo animal, or wild animal.